This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Calcium antagonist in hypertension

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Calcium antagonists are usually employed as second line agents in the treatment of hypertension. They are as effective as other hypertensive drugs when used in appropriate doses and may be, in general, used in combination with them.

Indications for the use of dihydropyridine calcium antagonists in the treatment of hypertension (1):

  • compelling indications - isolated systolic hypertension in elderly patients
  • possible indications - angina, elderly patients

Indications for the use of rate limiting calcium antagonists include (1):

  • compelling indications - angina
  • possible indications - myocardial infarction

Contraindications to the use of rate limiting calcium antagonists include (1):

  • possible contraindication - combination with beta-blockade
  • compelling contraindication - heart block, heart failure

Verapamil (or diltiazem) SHOULD NOT be combined with beta-blockade on account of it's tendency to cause heart block and impair ventricular contractility.

Reference:

  • BMJ (1999), 319, 630-5.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.